New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
Recruiting
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Northwell Health, Manhasset, New York
Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastasis From Malignant Melanoma of Skin (Disorder), Metastasis From Malignant Tumor of Bladder (Disorder), Metastasis From Malignant Tumor of Liver, Metastatic Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Recruiting
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Glofitamab (a type of immunotherapy) * Obinutuzumab (a type of immunotherapy)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Recruiting
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Memorial Sloan Kettering Cancer Center (Site: 840117), New York, New York
Conditions: Astrocytoma, Oligodendroglioma
GAMBIT Task with PTSD and Healthy Control Participants
Recruiting
This is a pilot study of a digital training task called GAMBIT. This study will be the first to examine potential relationships between GAMBIT task completion and brain circuit flexibility, behavior, and symptoms in participants with PTSD.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/12/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Posttraumatic Stress Disorder
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/11/2025
Locations: NYU Langone Health, New York, New York
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
Recruiting
The researchers are doing this study to compare two different types of group therapy and find out whether they are effective approaches for helping breast cancer survivors manage joint pain caused by aromatase inhibitors (AI). This type of joint pain is called AI-associated arthralgia, or AIA, and it is common in people taking AIs. AIA and its associated symptoms can make some people decide to stop taking their medication. The study will look at the effects of two different types of group therap... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack, New York
Conditions: Breast Cancer Survivor
Efficacy of Nanodropper-mediated Topical Anesthetic
Recruiting
The goal of this clinical trial is to compare the onset and duration of numbness of the surface of the eye following the administration of numbing drops, called proparacaine, using either a standard eye drop bottle or a "Nanodropper" adaptor. The Nanodropper is designed to administer smaller-sized drops, or microdrops. Participants will: 1. Complete a baseline eye exam. 2. Receive a numbing drop using a standard dropper in one eye and the Nanodropper in the other eye. 3. Have their eyes tested... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Corneal Diseases, Effectiveness of Microdrops
Gadopiclenol vs Gadoxetate MRI for Liver Lesions
Recruiting
The overall purpose of this study is to establish noninferiority of gadopiclenol MRI compared to gadoxetate MRI in terms of image quality and lesion detection/conspicuity in patients undergoing clinically indicated liver MRI in a prospective study. The research will be utilizing MRI; with enrollment goal of 75 subjects over the course of two years.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
01/10/2025
Locations: BMEII, New York, New York
Conditions: Liver Lesion
A Phase 1 Study of ADI-001 in Autoimmune Disease
Recruiting
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/10/2025
Locations: The Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York
Conditions: Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Recruiting
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments. Primary Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pe... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
01/10/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Breast Cancer
Imaging With a PET Agent for Detection of Cancers of the Head and Neck
Recruiting
The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Head and Neck Cancer